LION TCR Logo (EUIPO, 02/02/2016)
EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark LION TCR was filed as Figurative mark on 02/02/2016 at the European Union Intellectual Property Office.
It was registered as a trademark on 07/13/2016.
The current status of the mark is "Trademark registered".
Logodesign (Wiener Klassifikation)
#Lions #Heads of animals of Series I
| Trademark form | Figurative mark |
| File reference | 015066251 |
| Application date | February 2, 2016 |
| Publication date | April 5, 2016 |
| Entry date | July 13, 2016 |
| Expiration date | February 2, 2026 |
Trademark owner
20 Maxwell Road, Maxwell House #07-08
069113 Singapore
SG
069113 Singapore
SG
Trademark representatives
Brienner Straße 50a
80333 München
DE
goods and services
1
Chemical adjuvants and reagents for use in science and immuno-assay testing (other than medicine); active chemical ingredients for use in the manufacture of anti-cancer drugs; assays and reagents for use in genetic research; cell line products, being replicating cells for medical and scientific research purposes and for the experimental production of pharmaceutical and biotechnological preparations; ingredients related to cell line products, including buffers, nutrients, synthetic chemicals and hormones, for medical and scientific research purposes and for experimental production of pharmaceutical and biotechnological preparations; plasmids, being DNA molecules for scientific research purposes and for experimental production of pharmaceutical and biotechnological preparations; viral vectors, being engineered viruses to deliver nucleic acids, genetic molecules, RNA or DNA for medical and scientific research purposes and for experimental production of pharmaceutical and biotechnological preparations; antibodies, T cells, modified T cells and T-Cell Receptors (TCRs) for scientific and research purposes; nucleic acids and genetic molecules encoding T-Cell Receptors (TCRs) for scientific and research purposes
5
Adjuvants for medical purposes; vaccines; vaccine adjuvants; pharmaceutical preparations; pharmaceutical preparations for the treatment of diseases, in particular diseases prevalent in Asia; pharmaceutical preparations, substances and products for the prevention and treatment of cancer; anti-cancer preparations; pharmaceuticals, vaccines and medical preparations for the treatment of virus-related tumours and chronic viral infections; pharmaceutical preparations for regulating the immune system; immunoassay reagents for medical use; pharmaceuticals for use in oncology; gene-modified pharmaceutical preparations; pharmaceutical preparations incorporating genetically modified active ingredients; antivirals; antiviral agents and preparations; pharmaceutical preparations namely antivirals; reagents for use in medical genetic testing; preparations for detecting genetic predispositions for medical purposes; cell line products for pharmaceutical purposes and for the production of pharmaceutical and biotechnological preparations; antibodies, T cells, modified T cells and T-Cell Receptors (TCRs) for medical purposes; nucleic acids and genetic molecules encoding T-Cell Receptors (TCRs) for medical purposes; diagnostic kits consisting primarily of antibodies, buffers, and reagents for use in disease testing; cell line products, being medicinal or pharmaceutical preparations; plasmids, being DNA molecules for medical purposes
42
Scientific and technological services and research and design relating thereto; drug discovery and drug development services; scientific research services; research and development of vaccines and medicines; research, development and engineering of antibodies, modified T cells and T-Cell Receptors (TCRs); laboratory services relating to the production of antibodies, T cells, modified T cells and T-Cell Receptors (TCRs), cell line products, viral vectors, plasmids, nucleic acids and genetic molecules; genetic research; scientific research in the field of genetics and genetic engineering; genetic engineering services; providing laboratory research services in the field of gene expression, namely, cancer biology; testing, inspection, research, or development of gene-modified pharmaceutical preparations and pharmaceutical preparations for gene therapy; providing medical and scientific research information in the fields of pharmaceuticals and genetics; research and development services in the field of immunology; researching and developing the use of antibodies, T cells, modified cells, modified T cells and T-Cell Receptors (TCRs) for the treatment of patients; information, consultancy and advisory services related to the aforesaid
44
Medical services; medical analysis services for the diagnosis and prognosis of cancers and other diseases; medical services connected with the treatment of cancers, virus-related tumours, chronic viral infections and diseases (including diseases prevalent in Asia); medical services relating to the removal, treatment, processing and introduction of human cells; medical services connected with the treatment of patients through the use of modified cells as therapeutic agents; medical services, namely the isolation, extraction and modification of human cells and reintroduction to patients as therapeutic agents for the treatment of cancers, virus-related tumours, chronic viral infections and diseases (including diseases prevalent in Asia); medical services related to the treatment of diseases, infections and cancers using antibodies, T cells, modified T cells and T-Cell Receptors (TCRs); medical and health services relating to DNA, genetics and genetic testing; medical therapy services; information, consultancy and advisory services related to the aforesaid
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| August 29, 2024 | Change Representative, Published | ||
| January 7, 2021 | Change Representative, Published | ||
| December 16, 2020 | Change Representative, Published |
ID: 11015066251